Mark Ensor

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

Brian J. Dillon, Víctor G. Prieto, Steven A. Curley et al. · Cancer · 2004 · 337 citations

Medicine, Cancer Biology, Oncology +17

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

Mark Ensor, Frederick W. Holtsberg, John S. Bomalaski et al. · PubMed · 2002 · 319 citations

Life Sciences, Biochemistry, Oncology +15

Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies

Paolo A. Ascierto, Stefania Scala, Giuseppe Castello et al. · Journal of Clinical Oncology · 2005 · 249 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +16

Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies

Francesco Izzo, Paolo Marra, Gerardo Beneduce et al. · Journal of Clinical Oncology · 2004 · 249 citations

Medicine, Oncology, Pharmacology +17

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

Frederick W. Holtsberg, Mark Ensor, Marion R. Steiner et al. · Journal of Controlled Release · 2002 · 160 citations

Pharmacy, Pharmaceutics, Pharmacology +12